Press Releases Ophirex Publishes Phase 2 Data in BMJ Global Health from the First Use of Varespladib to Treat Venomous Snakebite Victims October 23, 2024 Ophirex Appoints Jeremy Gowler as Chief Executive Officer July 15, 2024 January 5, 2023 Ophirex Completes $37 Million Series B Financing to Advance Development of Broad-Spectrum Snakebite Treatment March 14, 2022 Ophirex Receives FDA Fast Track Designation for Varespladib Treatment for Snakebite August 16, 2021 Ophirex Enrolls First Patient in BRAVO Study for Snakebite Treatment March 2, 2020 Ophirex Receives Wellcome Trust Award to Advance Clinical Development of Novel Snakebite Treatment August 28, 2017 Ophirex Licenses Lilly - Shionogi Data for Novel Snakebite Treatment Development Program
